SAN DIEGO–(BUSINESS WIRE)–iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The collaboration leverages iXCells’ iPSCore platform, which enables the large-scale generation of well-characterized patient-derived iPSC lines, to support the discovery and d
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
